EuroBiotech: More Articles of Note


> Nordic Nanovector delayed the readout from its phase 2b follicular lymphoma trial in response to slow patient enrollment. The delay moves the readout beyond when analysts at Jefferies expect the biotech’s current cash reserves to run dry. Release 

> PPF bought a 19.2% stake in CAR-T biotech Autolus. The Czech investment group owns most of another biotech, Sotio. Statement

> Lytix Biopharma appointed Øystein Rekdal as CEO. Rekdal replaces Edwin Klumper, who is taking early retirement. Release


CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

> Poxel shared detailed data from a Japanese phase 3 trial of imeglimin in Type 2 diabetics. Metavant has the rights to the drug in the U.S. and Europe. Statement 

> Theranexus enrolled the last subject in a phase 1b trial of its treatment of neurocognitive disorders related to Alzheimer's disease. Release 

> Ose Immunotherapeutics received a €5.4 million ($6 million) milestone payment in relation to its Boehringer Ingelheim-partnered SIRPa-antagonist and myeloid checkpoint inhibitor. Statement 

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.